Talk:Bapineuzumab

Ideal sources for Wikipedia's health content are defined in the guideline Wikipedia:Identifying reliable sources (medicine) and are typically review articles. Here are links to possibly useful sources of information about Bapineuzumab.

PubMed provides review articles from the past five years (limit to free review articles)
The TRIP database provides clinical publications about evidence-based medicine.
Other potential sources include: Centre for Reviews and Dissemination and CDC

Does bapineuzumab work?

I have made several review of the literature on bapineuzumab for different projects (I am in medical school). While the drug seemed/seems very promising, one of the key problem is that it does not improve cognition. While many scientists make the claim that it is revolutionary, I believe it is misleading to state that studies have already proven its efficacy. Thus I have removed a statement saying so in the article. The only thing, which has been shown and accepted is bapineuzumab removes amyloid plaques, this is not equal to not having cognitive problems anymore.--Bastilleday uky (talk) 15:05, 10 April 2009 (UTC)[reply]

I can offer anecdotal evidence only. My mother was part of the recent clinical trial, and is still taking bapineuzumab. It is obvious to everyone involved that her cognitive function and short-term memory has been returning. It's a slow process, but the improvements have been substantial and dramatic. —Aetheling (talk) 19:20, 11 October 2010 (UTC).[reply]

DR6

The discussion of DR6 is based on a single publication that has yet to be replicated and is irrelevant. —Preceding unsigned comment added by 155.91.45.231 (talk) 16:35, 16 September 2010 (UTC)[reply]

Would be nice to have that study linked here for future reference. --Dan|^(talk) 10:00, 8 December 2010 (UTC)[reply]

potential resource

Pharmaceutical promise "Two monoclonal antibodies to treat Alzheimer’s disease — solanezumab and bapineuzumab—would be a big hit if they reported positive results from phase III trials in 2012. Both bind to the amyloid-β peptides that make up the protein plaques seen in the brains of people with the disease. Meanwhile, the US Food and Drug Administration will once again consider the thorny issue of approving obesity drugs: it rejected one last year because of worries over side effects. It will also decide whether to approve a pioneering drug for cystic fibrosis, ivacaftor, made by Vertex Pharmaceuticals of Cambridge, Massachusetts. The drug works only for people with a particular genetic mutation, but would be the first to treat the disease’s underlying cause, rather than its symptoms. And Blockbuster Drugs will continue to lose patent protection, including the anticlotting Plavix (clopidogrel) and the antipsychotic Seroquel (quetiapine)."

Internal links ...

99.181.147.68 (talk) 05:50, 4 January 2012 (UTC)[reply]

Sid Gilman

Stub created at Sid Gilman, just to fix an incorrect redirect. Needs work. Needs everything. Andy Dingley (talk) 20:36, 24 February 2014 (UTC)[reply]